TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Immuron Announces Clinical Trial Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Steven Lydeamore
Immuron Announces Clinical Trial Update

Immuron Limited submitted an Investigational New Drug (IND) application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company's Travelan® P2TD study results are delayed until November 2025 due to government shutdown, with potential implications for future dosing strategies.

Insights
PFE   positive

Listed as a key market player with strong potential in developing advanced anti-inflammatory treatments


IMRN   neutral

Company is progressing clinical trials and regulatory submissions, with some delays but continuing active development of pharmaceutical products